ReviewVeterinary immunology and immunopathology2008
Advances in FIV vaccine technology.
Review in Veterinary immunology and immunopathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge.Journal of feline medicine and surgery · 2010Trial
- Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector.Vaccines · 2022Article
- Article
- Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.Viruses · 2018Review
- Formation of RNA Granule-Derived Capsid Assembly Intermediates Appears To Be Conserved between Human Immunodeficiency Virus Type 1 and the Nonprimate Lentivirus Feline Immunodeficiency Virus.Journal of virology · 2018Article
- FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.NPJ vaccines · 2018Article
- Article
- Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.Human vaccines & immunotherapeutics · 2015Article
- Article
- The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis.Frontiers in immunology · 2014Review
- Immunization against small ruminant lentiviruses.Viruses · 2013Review
- Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection.Retrovirology : research and treatment · 2012Article
- Review
- Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine.Veterinary immunology and immunopathology · 2011Review
- Identification of amino acid residues important for heparan sulfate proteoglycan interaction within variable region 3 of the feline immunodeficiency virus surface glycoprotein.Journal of virology · 2011Article
- Fine definition of the CXCR4-binding region on the V3 loop of feline immunodeficiency virus surface glycoprotein.PloS one · 2010Article
- Feline immunodeficiency virus model for designing HIV/AIDS vaccines.Current HIV research · 2010Review
- The utilization of humanized mouse models for the study of human retroviral infections.Retrovirology · 2009Review
- Article
- Vaccine-induced enhancement of viral infections.Vaccine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Advances in vaccine technology are occurring in the molecular techniques used to develop vaccines and in the assessment of vaccine efficacy, allowing more complete characterization of vaccine-induced immunity correlating to protection. FIV vaccine development has closely mirrored and occasionally surpassed the development of HIV-1 vaccine, leading to first licensed technology. This review will discuss technological advances in vaccine designs, challenge infection assessment, and characterization of vaccine immunity in the context of the protection detected with prototype and commercial dual-subtype FIV vaccines and in relation to HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.